WHITEHOUSE STATION, N.J. (AP) — Sales of Merck & Co.'s blockbuster cholesterol drug Vytorin likely will continue to fall amid rising competition from rival brands and generic versions in the same class of pills.
That's the view of an analyst after the drugmaker said an interim analysis halfway through a long study of the controversial drug didn't find serious safety problems.
Bernstein Research analyst Tim Anderson says even though a safety monitoring board decided the study should continue, the study might still show Vytorin works no better than a much-cheaper generic version of Zocor.
Vytorin combines Vytorin and a different type of cholesterol pill, Zetia. Merck hopes the study will show Vytorin prevents heart attacks, strokes and deaths more than Zocor alone.